Mary Tagliaferri, MD
About Mary Tagliaferri, MD
Mary Tagliaferri, M.D., is the Chief Medical Officer at Nektar with over 20 years of experience in pharmaceutical drug development, focusing on oncology and women's health.
Mary Tagliaferri, M.D. Title and Current Role
Mary Tagliaferri, M.D. serves as the Chief Medical Officer at Nektar. In this role, she provides clinical strategy guidance and oversees several key areas, including medical affairs, key clinical investigator relationships, and medical writing and publication functions. Her extensive experience in these domains makes her a valuable asset to Nektar's ongoing projects.
Mary Tagliaferri, M.D. Expertise in Pharmaceutical Drug Development
With over 20 years of experience in pharmaceutical drug development, Mary Tagliaferri, M.D. has specialized in oncology and women's health. She holds extensive regulatory expertise, having provided strategic development leadership and overseen regulatory affairs for multiple high-profile projects. Her insights into clinical strategy and regulatory compliance have been integral to the success of many initiatives in the industry.
Mary Tagliaferri, M.D. Contributions to Nektar Therapeutics
At Nektar Therapeutics, Mary Tagliaferri, M.D. plays a crucial role in the strategic development of the company's immuno-oncology portfolio, especially for bempegaldesleukin. In addition to this, she serves as the strategic development leader for Nektar's clinical collaboration with Bristol-Myers Squibb. Her leadership has been pivotal in defining and executing clinical strategies and ensuring successful collaborations.
Mary Tagliaferri, M.D. Previous Roles and Achievements
Before joining Nektar, Mary Tagliaferri, M.D. served as Chief Medical Officer at KangLaiTe USA and co-founded BioNovo, where she was President and Chief Medical Officer. At BioNovo, she led the company's clinical drug development strategy and managed global regulatory affairs, data management, biostatistics, and clinical operations. She also worked as a clinical and regulatory consultant to InterMune prior to its acquisition by Roche. Her work in these roles has earned her recognition, including the 2012 State of California Woman of the Year award for her contributions to clinical research in women's health and mentorship of women in biotechnology.
Mary Tagliaferri, M.D. Education
Mary Tagliaferri, M.D. received her B.S. degree from Cornell University and her M.D. from the University of California, San Francisco (UCSF). Her academic background provided a strong foundation for her extensive career in the pharmaceutical and biotechnology industries.